Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.

Vasc Health Risk Manag · 2016 · PMC5118038 · PMID 27895487

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

After a 5.5-year follow-up, the trial was stopped prematurely on the advice of the Data Safety Monitoring Committee because of highly significant outcome benefits in favor of the amlodipine/perindopril group.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.